1. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma.
- Author
-
Andreassen M, Ilett E, Wiese D, Slater EP, Klose M, Hansen CP, Gercke N, Langer SW, Kjaer A, Maurer E, Federspiel B, Kann PH, Bartsch DK, and Knigge U
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cohort Studies, Cytodiagnosis, Denmark, Endosonography, Female, Humans, Insulinoma pathology, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms pathology, Patient Care Planning standards, Retrospective Studies, Sensitivity and Specificity, Tomography, X-Ray Computed, Treatment Outcome, Ultrasonography, Young Adult, Insulinoma diagnosis, Insulinoma surgery, Pancreatectomy methods, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms surgery, Preoperative Care methods
- Abstract
Introduction: Diagnosis and pathological classification of insulinomas are challenging., Aim: To characterize localization of tumors, surgery outcomes, and histopathology in patients with insulinoma., Methods: Patients with surgically resected sporadic insulinoma were included., Results: Eighty patients were included. Seven had a malignant tumor. A total of 312 diagnostic examinations were performed: endoscopic ultrasonography (EUS; n = 59; sensitivity, 70%), MRI (n = 33; sensitivity, 58%), CT (n = 55; sensitivity, 47%), transabdominal ultrasonography (US; n = 45; sensitivity, 40%), somatostatin receptor imaging (n = 17; sensitivity, 29%), 18F-fluorodeoxyglucose positron emission tomography/CT (n = 1; negative), percutaneous transhepatic venous sampling (n = 10; sensitivity, 90%), arterial stimulation venous sampling (n = 20; sensitivity, 65%), and intraoperative US (n = 72; sensitivity, 89%). Fourteen tumors could not be visualized. Invasive methods were used in 7 of these 14 patients and localized the tumor in all cases. Median tumor size was 15 mm (range, 7 to 80 mm). Tumors with malignant vs benign behavior showed less staining for insulin (3 of 7 vs 66 of 73; P = 0.015) and for proinsulin (3 of 6 vs 58 of 59; P < 0.001). Staining for glucagon was seen in 2 of 6 malignant tumors and in no benign tumors (P < 0.001). Forty-three insulinomas stained negative for somatostatin receptor subtype 2a., Conclusion: Localization of insulinomas requires many different diagnostic procedures. Most tumors can be localized by conventional imaging, including EUS. For nonvisible tumors, invasive methods may be a useful diagnostic tool. Malignant tumors showed reduced staining for insulin and proinsulin and increased staining for glucagon., (Copyright © 2019 Endocrine Society.)
- Published
- 2019
- Full Text
- View/download PDF